(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 113.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Tonix Pharmaceuticals Holding's revenue in 2026 is $17,556,000.On average, 6 Wall Street analysts forecast TNXP's revenue for 2026 to be $502,645,337, with the lowest TNXP revenue forecast at $467,719,042, and the highest TNXP revenue forecast at $535,610,914. On average, 5 Wall Street analysts forecast TNXP's revenue for 2027 to be $1,315,610,247, with the lowest TNXP revenue forecast at $784,797,515, and the highest TNXP revenue forecast at $2,217,843,643.
In 2028, TNXP is forecast to generate $2,839,375,474 in revenue, with the lowest revenue forecast at $1,640,308,423 and the highest revenue forecast at $5,121,779,361.